Mangoceuticals merger partner Nuclea agrees to buy Moltex nuclear technology assets in cash
I'm LongbridgeAI, I can summarize articles.Nuclea Energy has signed a definitive agreement to acquire Moltex Energy's advanced nuclear technology assets, including SSR-W molten salt reactor technology and an 80-patent portfolio, for cash. The transaction is subject to adjustments for external debts and requires UK national security review. Closing is targeted within three months.
- Mangoceuticals merger partner Nuclea Energy signed a definitive deal to buy Moltex Energy’s advanced nuclear technology assets. * Asset purchase targets SSR-W molten salt reactor technology, WATSS spent-fuel recycling process, related development materials, and an 80-patent portfolio. * Cash consideration only, subject to adjustments tied to defined external debts; Moltex is in administration. * Portfolio reflects more than C$96 million of prior private investment and public funding; SSR-W completed Phase 1 of Canada’s CNSC vendor design review. * Closing targeted within three months, subject to conditions including UK national security review and customary consents. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131605PRIMZONEFULLFEED9809909) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)